// App-Quantinova.ai

BIOM-35 : A NEW PRECISION-MEDICINE APPROACH TO PREDICT TUMOR TREATMENT RESPONSE IDENTIFIES IN GLIOBLASTOMA A 17 GENE SIGNATURE PROGNOSTIC OF TMZ RESPONSE AND SURVIVAL WITH ROBUST PREDICTIVE VALUE

Researchers

Presenter

  • Mariangela Morelli

Principal Investigators

  • Anna Luisa Di Stefano

  • Alberto Picca

  • Francesca Lessi

  • Orazio Santonocito

  • Michele Menicagli

  • Francesco Pasqualetti

  • Sara Franceschi

  • Paolo Aretini

  • Marc Sanson

  • Chiara Maria Mazzanti

Medical Centers

  • Fondazione Pisana per la Scienza, Pisa, Italy

  • Department of Oncology, University of Oxford, Oxford, United Kingdom

  • Sorbonne Université, Paris Brain Institute, Paris, France

  • Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France

  • Neurosurgical Department of Spedali Riuniti di Livorno, Livorno, Italy

Locations

  • Italy

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gliomas

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • O-6-methylguanine DNA methyltransferase

Drug/Treatment

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved